IFNA1 and systemic lupus erythematosus: There is also a rapidly growing panel of potential biomarkers of SLE risk or early disease including anti-dense fine speckled 70 (DFS70) as a rule-out SARD test (173), anti-C1q antibodies as a rule-in test (174), cytokines and chemokines (175, 176), IFN signature (177), as well as markers of complement activation (178).